@article{0af9dbc21b2d46578d435e48030d7317,
title = "Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer",
abstract = "This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.",
author = "Spring, {Laura M.} and Hyo Han and Liu, {Minetta C.} and Erika Hamilton and Hanna Irie and Santa-Maria, {Cesar A.} and James Reeves and Peng Pan and Ming Shan and Yongqiang Tang and Graham, {Julie R.} and Sebastien Hazard and Ellisen, {Leif W.} and Isakoff, {Steven J.}",
note = "Funding Information: L.M.S. reports personal fees from Novartis, Puma, Lumicell and Avrobio; travel support from Tesaro and Merck; research funding to institution from Tesaro and Merck. H.H. reports research funding to institution from Arvinas, AbbVie, Bristol-Myers Squibb, Daiichi Pharma, GSK, Karyopharm, Prescient, G1 Therapeutics, Marker Therapeutics, Novartis, Horizon Pharma, Quantum Leap Healthcare Collaborative, Pfizer, Zymeworks and Seattle Genetics; grants from the Department of Defense; and personal fees from Speaker{\textquoteright}s Bureau for Lilly. M.C.L. reports research funding to institution from Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics and Tesaro; funding to institution for participation in advisory boards for Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics and Syndax. E.H. reports research funding to institution from OncoMed, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millennium, Medivation, Acerta Pharma, Sermonix Pharmaceuticals, Aravive, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, Fujifilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova Therapeutics, Dana Farber Cancer Hospital, Hutchinson Medipharma, MedImmune, Seagen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicines, Takeda, Merus, Regeneron, Arvinas, StemcentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, AbbVie, Nucana, Leap Therapeutics, Zenith Epigenetics, Harpoon, Orinove, AstraZeneca, Tesaro, Macrogenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, GI Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxikon and Amgen; fees for consulting/advisory role to institution from Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo and AstraZeneca; travel/accommodation expenses from AstraZeneca, Lilly, Pfizer, Puma and Daiichi Sankyo. H.I. reports no conflicts of interest. C.A.S.-M. reports grants from Pfizer, AstraZeneca and Bristol-Myers Squibb; research funding to institution from Novartis; and advisory boards for Bristol-Myers Squibb, Seattle Genetics, Athenex and Genomic Health. J.R. reports grants to institution from Eli Lilly, Tesaro, Sarah Cannon, TG Therapeutics, Genentech, Celgene, Merck, Bristol-Myers Squibb, Boston Biomedical Inc., AstraZeneca, Novocure, Calithera Biosciences, Novartis, Guardant Health, Acerta Pharma, Rhizen Pharmaceuticals, Takeda Pharmaceuticals, Onconova Therapeutics, Sanofi and CTI Biopharma; grants from Daiichi Sankyo, Seattle Genetics, Taiho Oncology, Odonate, Boehringer Ingelheim, Macrogenics, Ipsen/Medpace, Beigene, Acerta, Verastem, Pharmacyclics, Medimmune, Jiangsu Hengrui Med, Arcus Biosciences, Calethera, Mirati, Pfizer, Immunogen, Karyopharm and GSK; speaker bureau fees and travel expenses from Eisai and Janssen; personal fees for advisory boards for Karyopharm, Polyphor and Bayer. P.P., M.S., S.H. and Y.T. are employees of and owners of shares/options in GSK. J.R.G. is an employee of and owner of shares/options in GSK, and reports stock ownership in Pfizer. L.W.E. reports no conflicts of interest. S.J.I. reports personal fees for consulting from AbbVie, Hengrui, Immunomedics, Mylan, Myriad, Puma, Seattle Genetics and Novartis. Funding Information: The present study was funded by GlaxoSmithKline (GSK). GSK contributed to study design, implementation, data collection, interpretation and analysis. All the authors had full access to the data upon request and had final responsibility for the decision to submit for publication. Medical writing support was provided by E. Mercadante and C. Kelly, of Fishawack Indicia Ltd, UK, part of Fishawack Health, funded by GSK. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = aug,
doi = "10.1038/s43018-022-00400-2",
language = "English (US)",
volume = "3",
pages = "927--931",
journal = "Nature Cancer",
issn = "2662-1347",
publisher = "Nature Research",
number = "8",
}